EMEA-001143-PIP01-11-M01

Key facts

Invented name
Cometriq
Active substance
cabozantinib
Therapeutic area
Oncology
Decision number
P/0134/2016
PIP number
EMEA-001143-PIP01-11-M01
Pharmaceutical form(s)
  • Age-appropriate oral solid dosage form
  • Capsule
  • hard
Condition(s) / indication(s)
Treatment of malignant solid tumours
Route(s) of administration
Oral use
Contact for public enquiries
Exelixis, Inc.
United States
Tel. +1 866 939 4041
Fax +1 650 837 8122
E-mail: pascale.dutailly@ipsen.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating